Incoming RNA Virus Nucleocapsids Containing a 5′-Triphosphorylated Genome Activate RIG-I and Antiviral Signaling  by Weber, Michaela et al.
Cell Host & Microbe
ArticleIncoming RNA Virus Nucleocapsids Containing
a 50-Triphosphorylated Genome
Activate RIG-I and Antiviral Signaling
Michaela Weber,1 Ali Gawanbacht,3 Matthias Habjan,3 Andreas Rang,4 Christoph Borner,5,6 Anna Mareike Schmidt,3,6,10
Sophie Veitinger,2 Ralf Jacob,2 Ste´phanie Devignot,1 Georg Kochs,3 Adolfo Garcı´a-Sastre,7,8,9
and Friedemann Weber1,3,6,*
1Institute for Virology
2Department of Cell Biology and Cell Pathology
Philipps-University Marburg, 35043 Marburg, Germany
3Department of Virology, University Freiburg, Hermann-Herder-Strasse 11, 79008 Freiburg, Germany
4Institute of Virology, Helmut-Ruska-Haus, University Hospital Charite´, Charite´ Campus Mitte, 10117 Berlin, Germany
5Institute of Molecular Medicine, Stefan-Meier-Strasse 17, 79104 Freiburg, Germany
6Centre for Biological Signalling Studies (BIOSS), Albert-Ludwigs University, 79104 Freiburg, Germany
7Department of Microbiology
8Department of Medicine, Division of Infectious Diseases
9Global Health and Emerging Pathogens Institute
Mount Sinai School of Medicine, New York, NY 10029, USA
10Present address: Institute of Molecular Systems Biology, ETH Zurich, 8093 Zurich, Switzerland
*Correspondence: friedemann.weber@staff.uni-marburg.de
http://dx.doi.org/10.1016/j.chom.2013.01.012SUMMARY
Host defense to RNA viruses depends on rapid intra-
cellular recognition of viral RNA by two cytoplasmic
RNA helicases: RIG-I and MDA5. RNA transfection
experiments indicate that RIG-I responds to naked
double-stranded RNAs (dsRNAs) with a triphos-
phorylated 50 (50ppp) terminus. However, the identity
of the RIG-I stimulating viral structures in an
authentic infection context remains unresolved. We
show that incoming viral nucleocapsids containing
a 50ppp dsRNA ‘‘panhandle’’ structure trigger anti-
viral signaling that commences with RIG-I, is
mediated through the adaptor protein MAVS, and
terminates with transcription factor IRF-3. Indepen-
dent of mammalian cofactors or viral polymerase
activity, RIG-I bound to viral nucleocapsids, under-
went a conformational switch, and homo-oligo-
merized. Enzymatic probing and superresolution
microscopy suggest that RIG-I interacts with the
panhandle structure of the viral nucleocapsids.
These results define cytoplasmic entry of nucleocap-
sids as the proximal RIG-I-sensitive step during
infection and establish viral nucleocapsids with a
50ppp dsRNA panhandle as a RIG-I activator.
INTRODUCTION
Host defenses to RNA viruses are dependent on rapid detection
by pathogen recognition receptors (PRRs). Intracellular recogni-
tion of virus infection is mediated by two cytoplasmic RNA heli-336 Cell Host & Microbe 13, 336–346, March 13, 2013 ª2013 Elseviecases: RIG-I and MDA5 (termed RIG-like receptors, RLRs) (Kato
et al., 2011). The binding of an RNA ligand to these PRRs leads to
phosphorylation and dimerization of interferon regulated factor 3
(IRF-3), which subsequently activates genes for type I interferons
(IFN-a/b) (Hiscott, 2007). These cytokines trigger the expression
of IFN-stimulated gene (ISG) products that have antiviral and
immunomodulatory activities (Randall and Goodbourn, 2008).
The infection cycle of RNA viruses consists of the phases
attachment, entry, messenger RNA (mRNA) transcription,
genome replication, assembly, and exit. Negative-strand RNA
viruses carry an RNA-dependent RNA polymerase (RdRp) within
their particles and immediately start transcribing their genome
after entering the cell. The protein products of this so-called
primary transcription then drive the replication of the genome
via a positive-sense intermediate. Positive-strand RNA viruses
do not carry an RdRp in their particles and directly translate their
genome after entry. The newly synthesized RdRp then produces
a negative-sense intermediate, mRNA, and progeny genome.
Usually, the genome of both negative- and positive-strand
RNA viruses is packaged by a viral nucleocapsid protein (often
called N).
Most studies on activation of RLRs were based either on
infection with RNA viruses undergoing a full replication cycle
or on transfection of cells with naked viral or synthetic RNAs.
The infection experiments established that RIG-I and MDA5
recognize mostly nonoverlapping subsets of viruses (McCartney
and Colonna, 2009). The RNA transfection experiments re-
vealed that RIG-I responds to long double-stranded RNA
(dsRNA) molecules, short dsRNAs with a triphosphorylated
50 (50ppp) terminus, and poly-U/UC-rich sequences, whereas
MDA5 activation is more dependent on branched dsRNA struc-
tures (Binder et al., 2011; Hornung et al., 2006; Kato et al., 2008;
Pichlmair et al., 2006, 2009; Saito et al., 2008; Schlee et al., 2009;
Schmidt et al., 2009). Despite these achievements, the questionr Inc.
Figure 1. IFN Response to Incoming Negative-Strand RNA Viruses
(A–D) Cells were treated with inhibitors, infected, incubated for 24 hr, and then
assayed for mRNA levels of IFN-b (left panels) and ISG56 (right panels) using
real-time RT-PCR. Here and in all following figures, mean values and SDs from
three independent experiments are shown. (A and B) IFN response in the
absence of viral genome replication. Cells were treated for 1 hr with 0 or
50 mg/ml CHX and then infected either with FLUAVDNS1 (FLUAV) and VSV (A)
or with RVFVDNSs::GFP (RVFV) and LACVdelNSs (LACV) (B). (C and D)
Requirement for virus entry. (C) Cells were treated for 1 hr with 0 or 50 mM
NH4Cl and then infected with RVFVDNSs::GFP. (D) Infection with different
types of VLPs. Cells were CHX treated and infected with tc-VLPs or the
equivalent amount of ghost VLPs. See also Figures S1–S2H.
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RIG-I Recognizes Encapsidated Viral 50ppp dsRNAof the natural RLR ligands (i.e., which viral structures are stimu-
lating the RLRs in the authentic infection context) is largely
unsolved. Two recent RNA fractionation studies showed that
full-length and shortened RNAs arising during genome replica-
tion of 50ppp-RNA viruses are natural stimulators of RIG-I
(Baum et al., 2010; Rehwinkel et al., 2010). However, it remained
open whether these RIG-I ligands were naked RNA side
products of viral genome replication or whether RIG-I could
also recognize nucleoprotein-encapsidated RNA, the main
viral structure in the infected cell. Our study presented here
addresses this problem and indicates that RIG-I is capable of
reacting to incoming, encapsidated RNA virus genomes. This
immediate early IFN response requires the viral 50ppp dsRNA
‘‘panhandle’’ structure but is independent of viral RNA synthesis.
RIG-I thereby directly interacts with the panhandle on the viral
nucleocapsids, switches conformation, oligomerizes, and trig-
gers the activation of IRF-3.
RESULTS
Our first aim was to identify the earliest infection step that trig-
gers IFN induction. In the hope of drawing conclusions on the
responsible viral determinant, we employed a set of RNA viruses
with different genomic features. Dependent on the particular
virus, a block of viral mRNA translation by cycloheximide (CHX)
has different effects on primary transcription and genome repli-
cation (Table S1 available online).
Entry of Negative-Sense RNA Viruses Can Activate IFN
Induction in the Absence of Replication
Influenza A virus (FLUAV) and vesicular stomatitis virus (VSV) are
negative-strand RNA viruses. Application of CHX allows particle
attachment, entry of nucleocapsids, and primary transcription,
but not genome replication (Figure S1). We measured the
virus-inducible genes for IFN-b and ISG56 in human A549 cells
by real-time RT-PCR. Figure 1A shows that both FLUAV and
VSV are strongly activating these genes, even when CHX was
applied. Thus, an IFN response can occur before the viruses start
replicating their genome.
To narrow down the IFN-relevant infection step, we repeated
the experiment using Rift Valley fever virus (RVFV) and La Crosse
virus (LACV). These bunyaviruses are peculiar in that their tran-
scription depends on concurrent translation (Raju et al., 1989).
CHX treatment arrests viral primary transcription at a very early
step, but had only a minor influence on IFN-b and ISG56 induc-
tion (Figure 1B). Apparently, not even a fully operating primary
transcription is required for triggering an IFN response.
Recent reports suggested that particle attachment or mem-
brane fusion can activate an antiviral response (Holm et al.,
2012; Noyce et al., 2011), although other groups did not observe
this in their systems (Handke et al., 2009; Spiropoulou et al.,
2007; Stoltz and Klingstro¨m, 2010). We employed several
methods to study the involvement of particle attachment. First,
we pretreated cells with NH4Cl, an agent that inhibits bunyaviral
entry into the cytoplasm (Filone et al., 2006) but does not impede
the IFN response (Figure S2A). As shown in Figure 1C, NH4Cl
almost entirely abrogated the host response to RVFV. Similarly,
three other bunyavirus entry inhibitors (de Boer et al., 2012) (Fig-
ure S2B–S2D), as well as virus inactivation by b-propiolactoneCell Ho(Figure S2E) or UV irradiation (Figure S2F), all led to a reduction
of IFN induction. In a complementary approach, we employed
two types of virus-like particles (VLPs) of RVFV. Complete
VLPs contain nucleocapsids with a reporter minigenome,
whereas ‘‘ghost’’ VLPs have just the N protein inside (Fig-
ure S2G). The complete VLPs, also called transcriptionally
competent (tc-) VLPs (Hoenen et al., 2011), are capable ofst & Microbe 13, 336–346, March 13, 2013 ª2013 Elsevier Inc. 337
Figure 2. Influence of the Viral 50ppp Group and of RIG-I
(A) Cells were CHX treated; infected with LACVdelNSs, PHV, or SFV; and
assayed as described in Figure 1.
(B) Innate response to VSV or LACVdelNSs by cells treated with CHX and with
siRNAs targeting MDA5 or RIG-I.
(C and D) MEFs lacking MDA5 (C) or RIG-I (D), and the corresponding
WT MEFs, were tested for their innate response to tc-VLPs. See also Figures
S3A–S3H.
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RIG-I Recognizes Encapsidated Viral 50ppp dsRNAprimary transcription, but not of replication (Habjan et al., 2009a).
tc-VLPs triggered IFN-b and ISG56 expression, even under
CHX (Figure 1D). Ghost VLPs, however, did not elicit any IFN
response, although they bind equally well to the cells (Fig-
ure S2H). These data indicate that, in our system, virus entry
or primary transcription is necessary and sufficient for IFN
induction.
The Immediate Early IFN Response Requires Viral
50Triphosphate RNA and RIG-I
All viruses used so far contained the RIG-I-activating 50ppp
group on their RNA genome (Habjan et al., 2008a; Hornung
et al., 2006; Pichlmair et al., 2006). To clarify the contribution of
the genome end, we employed two RNA viruses that lack this
feature (see Table S1). Prospect Hill virus (PHV; family Bunyavir-
idae) has a monophosphate at the 50 end (Garcin et al., 1995;
Habjan et al., 2008a). Semliki Forest virus (SFV; family Togaviri-
dae) has a 50 cap structure (McInerney et al., 2005). CHX inhibits
PHV in the same way as the related RVFV or LACV (Figure S1).
SFV is a positive-strand RNA virus (i.e., its genome is directly
translated after entry). In the absence of CHX, PHV minimally
activated the IFN-b promoter and moderately activated ISG56
transcription, as expected (Prescott et al., 2005), whereas the
IFN response to SFV was similar to LACV (Figure 2A). Strikingly,
application of CHX completely abrogated the IFN response to
both PHV and SFV. In line with this, the transcription factor
IRF-3 was activated under CHX-restricted infection with VSV
or LACV, but not PHV or SFV (Figure S3A–S3F). Thus, IFN
responses to incoming RNA virus nucleocapsids occur only if
the genome contains a 50ppp.
To pin down the responsible RLR, we evaluated the influence
of specific knockdowns. Cells were transfected with small inter-
fering RNAs (siRNAs) forMDA5, RIG-I, or a control (Figure S3G),
treated with CHX, and infected with VSV or LACV. Knockdown of
RIG-I, but not ofMDA5, impaired IFN induction by VSV and LACV
nucleocapsids (Figure 2B). To bolster these findings, we utilized
mouse embryo fibroblasts (MEFs) deficient in RIG-I or MDA5.
Because these cells were extremely sensitive to CHX (data not
shown), we employed tc-VLPs as a virus system halted at the
stage of primary transcription. MEFs lacking MDA5 displayed
similar host responses to tc-VLPs as WT MEFs (Figure 2C).
MEFs lacking RIG-I, by contrast, completely lost their ability to
respond (Figure 2D). Knockout of MAVS (Seth et al., 2005), the
adaptor common to MDA5 and RIG-I, had a similar impact (Fig-
ure S3H). Taken together, these data suggest that nucleocap-
sids of 50ppp RNA viruses activate an IFN response via the
RIG-I-MAVS signaling cascade.
Activation of RIG-I
Binding of a target RNA to RIG-I triggers a conformational switch
(Saito et al., 2007; Takahasi et al., 2008) and oligomerization
(Binder et al., 2011; Saito et al., 2007). The conformational switch
is indicated by partial resistance to trypsin digestion. We
observed that the full infection cycle of SFV, VSV, and LACV
leads to the emergence of trypsin-resistant fragments of RIG-I
(Figure 3A). When cells had been pretreated with CHX, VSV
and LACV still triggered the conformational switch of RIG-I,
whereas SFV infection had no effect (Figure 3B). The oligomeri-
zation of RIG-I was assayed by native PAGE. In uninfected cells,338 Cell Host & Microbe 13, 336–346, March 13, 2013 ª2013 Elsevieonly monomers of RIG-I were detected (Figure 3C). Curiously,
also in SFV-infected cells only monomeric RIG-I is present (Fig-
ure 3D), although RIG-I switches conformation (see Figure 3A).
For the 50ppp RNA viruses VSV and LACV, both the full and
the CHX-aborted replication cycle resulted in RIG-I oligomeriza-
tion (Figures 3E and 3F). The 50-monophosphorylated PHV, by
contrast, only weakly activated the conformational switch (Fig-
ure 3G) and not the oligomerization (Figure 3H). Taken together,
these results suggest that RIG-I is rapidly and strongly activated
by viral nucleocapsids in the absence of genome replication,
provided the genome is carrying a 50ppp group.
Interaction between RIG-I and Incoming Nucleocapsids
We wondered whether RIG-I could form a complex with viral
50pppRNAnucleocapsids. As an experimental system,we chose
the setup closest to the immediate early phase (arrested primary
transcription), namely infection with bunyaviruses such as LACV
under CHX treatment. The N protein thereby served as a marker
for viral nucleocapsids. Using confocal immunofluorescencer Inc.
Figure 3. Activation of RIG-I
(A and B) Conformational switch. A549 cells were
treated with 0 (A) or 50 mg/ml CHX (B), infected
with the indicated viruses, and lysed 6 hr later. Cell
extracts were subjected to limited trypsin diges-
tion (right panels) or left untreated (left panels).
Upper panels show western blot analysis with
an anti-RIG-I antibody, and lower panels show
Ponceau S staining as loading control.
(C–F) Oligomerization. A549 cells were left
untreated (UT) or treated with 50 mg/ml CHX. Then,
cells were either mock infected (C) or infected with
SFV (D), VSV (E), or LACVdelNSs (F). At the
indicated time points, RIG-I was analyzed by
native PAGE and western blotting. As positive
and negative controls, VSV-infected cells at 6 hr
postinfection (CTRL) and mock-infected cells,
respectively, were used.
(G and H) PHV and RIG-I. A549 cells infected with
LACVdelNSs or PHV were monitored for the RIG-I
conformation at 6 hr postinfection (G) or for RIG-I
oligomerization over a time course (H). The ratio of
oligomers to monomers (normalized to the actin
signal and in relation to mock cells) is indicated
below the blots (fold induction).
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particles as individual dots in the cytoplasm (Figure 4A). These
LACV N dots colocalize with RIG-I (Figure S4A), as indicated by
overlay pictures and intensity profiles of the fluorescence signals.
Quantitative analysis revealed that LACV nucleocapsids colocal-
ize with RIG-I in 51% of the cases but with the cytoplasmic
control protein glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) in 33% of the cases (data not shown). N/RIG-I colocal-
ization was also observed in cells undergoing a full replication
cycle (data not shown), in agreement with observations on
FLUAV (Onomoto et al., 2012). The incoming LACV nucleocap-
sids also colocalized with peroxisomes (Figure S4B), cyto-
plasmic organelles involved in immediate early activation of
RIG-I (Dixit et al., 2010). Coimmunoprecipitation demonstrated
that RIG-I was capable of binding the incoming LACVnucleocap-
sids (Figure 4B). The same RIG-I/LACV nucleocapsid interaction
was observedwhen a full replication cycle was allowed, whereasCell Host & Microbe 13, 336–34MDA5 did not interact under any condi-
tion (data not shown). Overexpressed N
protein, by contrast, could not be precip-
itated via RIG-I (Figure S4C). We per-
formed similar experiments with RVFV.
Again, incoming nucleocapsids triggered
the conformational switch and oligomeri-
zation of RIG-I and activated IRF-3 (Fig-
ure S4D). Moreover, the nucleocapsids
of RVFV colocalized (Figure S4E) and
coprecipitated with RIG-I (Figure S4F).
Strikingly, incoming nucleocapsids could
be forced into a high-molecular-weight
RIG-I complex. TheATPanalogADP,AlF3
traps RIG-I in an RNA-bound closed
conformation unable to cycle between
the different states (Kowalinski et al.,2011). When CHX-treated and infected cells were incubated
with ADP,AlF3, the oligomers of RIG-I shifted from a smear into
a single high-molecular-weight band (Figure 4C, upper panels).
Probing of the lysates for the viral Nprotein revealed a similar shift
from an oligomeric state to a high-molecular-weight complex
(Figure 4C, lower panels). This was true for LACV as well as for
RVFV, indicating a general phenomenon. Together, these find-
ings demonstrate that RIG-I is able to associate with nucleocap-
sids of 50ppp RNA viruses directly after entry into the cell, leading
to RIG-I activation and innate immune signaling.
Nucleocapsid Binding and Activation of RIG-I Are
Independent of Mammalian Cofactors
The RIG-I/nucleocapsid interaction could either be direct or
mediated by one of the cellular cofactors of RIG-I (Kato et al.,
2011; Kok et al., 2011; Miyashita et al., 2011). To distinguish
between these possibilities, we employed an insect cell system.6, March 13, 2013 ª2013 Elsevier Inc. 339
Figure 4. Interaction of RIG-I with LACV Nucleocapsids
(A) Colocalization analysis. CHX-treated A549 cells were infected with LACVdelNSs and analyzed 5 hr later by double immunofluorescence using antisera against
LACV N (green channel) or RIG-I (red channel). Cell nuclei were counterstained with DAPI (blue channel). The square area of the inset is digitally magnified on the
right hand side. Three fluorescence intensity profiles are shown on the bottom.
(B) Coimmunoprecipitation. CHX-treated A549 cells were infected with LACVdelNSs (moi 10), lysed 5 hr later, and subjected to IP and western blot analysis using
antibodies against p21 (negative control), LACV N, and RIG-I. As input control, 10% of the cell lysate were analyzed in parallel (left lanes).
(C) ADP-aluminum fluoride trapping. CHX-treated A549 cells were infected with LACVdelNSs (left panels) or RVFVDNSs::REN (right panels). At 5 hr postinfection,
lysates were incubated with ADP,AlF3 and analyzed by native PAGE andwestern blot using antibodies against RIG-I (upper panels) or viral N (lower panels). Lines
indicate oligomers, arrowheads monomers, and arrows point toward high-molecular-weight complexes. See also Figures S4A–S4F.
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RIG-I Recognizes Encapsidated Viral 50ppp dsRNADrosophila melanogaster cells are a useful tool to reconstitute
mammalian signaling complexes in a background-free setting
(Yang and Reth, 2012) and are infectable with RVFV (Kortekaas
et al., 2011). When human RIG-I was expressed in Drosophila
D.mel-2 cells, conformational switching and oligomerization
were observed after infection with RVFV (Figures 5A and 5B).
RIG-I was also activated in vitro by mixing of lysates from RIG-
I-transfected D.mel-2 cells with lysates of infected D.mel-2 cells
(Figure 5C). Coimmunoprecipitation experiments demonstrated
binding of RIG-I to viral nucleocapsids in the Drosophila system
(Figure 5D). Again, this nucleocapsid interaction was indepen-
dent of whether RIG-I contacted RVFV during authentic virus
infection or whether lysates containing either RIG-I or RVFV
nucleocapsids were mixed in vitro. Thus, activation and nucleo-
capsid interaction of RIG-I occur in a direct manner and without
the contribution of a mammalian cofactor.
Nucleocapsid-Borne 50ppp-dsRNA Is Necessary and
Sufficient for RIG-I Activation
Our experiments with bunyaviruses and CHX implicated that the
transcriptional activity of nucleocapsids may not be relevant for
RIG-I activation. However, CHX still allows some abortive tran-
scription (Raju et al., 1989). To clarify whether RIG-I requires
this residual RNA synthesis, we performed several experiments.
First, we depleted the cellular NTP pool with the compounds
Brequinar (BRQ; inhibits pyrimidine synthesis), mycophenolic
acid (MA; reduces GTP levels), pyrazofurin (PYF; reduces CTP340 Cell Host & Microbe 13, 336–346, March 13, 2013 ª2013 Elsevieand UTP levels), or cyclopentenylcytosine (CPEC; depletes the
CTP pool) (Linke et al., 1996; Qing et al., 2010). Each of these
inhibitors affected viral RNA synthesis (Figure S5A). Nonethe-
less, even when combinedwith CHX, neither inhibitor diminished
RIG-I activation by LACV (Figure 6A). In fact, some of the com-
pounds slightly increased RIG-I activation and enhanced the
activation of IRF-3 (Figure 6A). Second, we depleted Drosophila
D.Mel-2 cell lysates containing either RIG-I or nucleocapsids
from NTPs by dialysis. When these dialyzed lysates were mixed
with each other, the conformational switch of RIG-I still occurred
and was enhanced by adding back ATP (Figure 6B). Third, we
employed nucleocapsids that had been isolated from purified
virus particles. Dialyzed RIG-I-containing D.Mel-2 extracts
were incubated with nucleocapsids of RVFV or LACV. The nucle-
ocapsids clearly induced the conformational switch of RIG-I
in vitro (Figure 6C). We conclude from these experiments that
viral transcription is not necessary for triggering RIG-I. As out-
lined above, the genomic RNA of bunyaviruses forms a
panhandle structure that has remarkable similarity with the
optimal 50ppp dsRNA ligand identified by transfection and
in vitro binding experiments (Figure S5B). Indeed, destroying
the dsRNA structures with RNase III or cleaving the triphos-
phates with a phosphatase abolished the ability of viral nucleo-
capsids to activate RIG-I (Figures 6D and 6E). Treatment with
the single-stranded RNA-specific RNase A, by contrast, had
no effect. Thus, a 50ppp dsRNA structure is indeed necessary
for the activation of RIG-I by nucleocapsids.r Inc.
Figure 5. Activation of RIG-I and Binding to Viral Nucleocapsids in Insect Cells
(A and B) D.Mel-2 cells expressing human RIG-I were infected for 72 hr with RVFVDNSs::REN (RVFV) and then tested for RIG-I conformation (A) and oligo-
merization (B).
(C) In vitro activation of RIG-I. Lysates of RIG-I-expressing D.Mel-2 cells weremixed with lysates of naive or RVFVDNSs::REN-infected D.Mel-2 cells and assayed
for RIG-I conformation.
(D) Coimmunoprecipitation. D.Mel-2 cells were either left naive (mock), or only infected with RVFVDNSs::REN (RVFV), only expressing RIG-I (RIG-I), or were both
expressing RIG-I and superinfected with RVFVDNSs::REN (RIG-I / RVFV). Combinations of lysates were subjected to IP and western blot analysis using anti-
bodies against RVFV N or RIG-I. As input control, 10% of the cell lysate were analyzed in parallel (left lanes).
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We employed ground state depletion (GSD) microscopy to
visualize the RIG-I/LACV nucleocapsid complex at 20 nm
resolution. This technique allows the display of individual nucleo-
capsids in their characteristic pseudocircular shape (Figure 7,
green channel), which is caused by the dsRNA panhandle for-
mation between the 50 and 30 genome ends (Obijeski et al.,
1976). Strikingly, accumulations of RIG-I are contacting nucleo-
capsids at a single site, lending the cocomplexes a ‘‘diamond
ring’’-like appearance (Figure 7, red channel). The negative
control GAPDH, by contrast, appeared to be more distant and
not accumulated at the nucleocapsids (Figure S6). These ob-
servations add additional weight to our hypothesis that RIG-I
binds the nucleocapsids via the terminal 50ppp dsRNA
panhandle.
DISCUSSION
The aim of our study was to clarify whether RIG-I is capable of
recognizing the RNA contained within incoming viral nucleocap-
sids. Our results indicate that this is indeed the case. RIG-I was
rapidly activated by viruses with the prototypical 50ppp dsRNA
panhandle structure, even when viral RNA synthesis was abol-
ished. Moreover, we detected a direct, single-site interaction
between RIG-I and nucleocapsids that was dependent on
50ppp dsRNA. Thus, viral nucleocapsids containing a 50ppp
panhandle represent a pathogen-associated molecular patternCell Ho(PAMP) for RIG-I. These findings advance the proximal RIG-I-
sensitive step of the viral infection cycle from the late stage
of genome replication (Baum et al., 2010; Rehwinkel et al.,
2010) to the immediate early step of nucleocapsids entering
the cytoplasm.
Erroneous, nonencapsidated replication products appear
during infection with FLUAV (Vreede et al., 2004). It is quite likely
that such naked replication products (Rehwinkel et al., 2010;
Vreede et al., 2004), along with defective interfering RNAs
(Baum et al., 2010; Killip et al., 2011; Strahle et al., 2006) and
newly formed nucleocapsids (this study), are responsible for
RIG-I induction under a full viral multiplication cycle. Previous
reports already demonstrated that genome replication is not an
absolute requirement for IFN induction (Killip et al., 2012; Marcus
and Sekellick, 1980) and that transfected nucleocapsids of the
50ppp viruses measles and VSV can activate IRF-3 even if they
are transcriptionally inactive (tenOever et al., 2002, 2004).
None of these studies, however, had addressed the involvement
of RIG-I or the requirement for a specific 50 genome end. Our
work extends their conclusions by showing that incoming viral
nucleocapsids can directly activate RIG-I, thus triggering a rapid
innate immune response.
It remains to be shown how RIG-I manages to access the
encapsidated viral RNA. Although the dsRNA-panhandle struc-
ture is covered by the viral polymerase (Resa-Infante et al.,
2011), some cytoplasmic exposure is necessary (e.g., to initiate
mRNA transcription). The global presence of RIG-I in thest & Microbe 13, 336–346, March 13, 2013 ª2013 Elsevier Inc. 341
Figure 6. Activation of RIG-I Solely
Depends on the Nucleocapsid-Borne
Panhandle Structure
(A) Effect of NTP withdrawal on activation of RIG-I
and IRF-3. Pretreated A549 cells were infected
with LACVdelNSs for 5 hr. Pretreatment with CHX
(50 mg/ml) was for 1 hr and with BRQ (10 mM,
stocks dissolved in DMSO), MA (10 mM, stocks
dissolved in methanol), PYF (10 mM, stocks dis-
solved in DMSO), or CPEC (5 mM, stocks dissolved
in DMSO) for 24 hr. RIG-I conformation (upper
two panels), RIG-I oligomerization (upper middle
panel), and IRF-3 phosphorylation (lower middle
panel) were monitored. Immunoblot for actin
served as loading control.
(B) RIG-I activation in dialyzed samples. Lysates
from D.Mel-2 cells expressing RIG-I (RIG-I) or in-
fected with RVFVDNSs::REN (RVFV) were dia-
lyzed against PBS, mixed with each other, and
incubated with or without ATP. After 1 hr incuba-
tion, mixes were subjected to the RIG-I confor-
mational switch assay.
(C) RIG-I activation by purified viral nucleocap-
sids (RNPs). Lysates from D.Mel-2 cells ex-
pressing RIG-I were dialyzed against PBS and
mixed with purified nucleocapsids from particles
of LACV (left panels) or RVFV (right panels).
Incubation with ATP and conformational switch
assay were performed as described for (B).
Equivalent fractions of gradient-purified super-
natants from mock-infected cells were used as
negative control (CTRL).
(D and E) Structural requirements for viral nucleocapsids to activate RIG-I. Lysates from RVFV-infected D.Mel-2 cells (D) or purified RVFV nucleocapsids (E) were
incubated with ATP and one of the indicated enzymes, namely RNase A (A), RNase III (III), or SAP. After mixing and incubation with dialyzed lysates from RIG-I-
expressing D.Mel-2 cells, the RIG-I conformational switch assay was performed. Negative controls (CTRL) were performed as described for (C). See also Figures
S5A and S5B.
Cell Host & Microbe
RIG-I Recognizes Encapsidated Viral 50ppp dsRNAcytoplasm and its high affinity for 50ppp dsRNA may allow to
rapidly entrap a panhandle, even if it is only briefly exposed.
Our observation of an early and substantial formation of RIG-I
oligomers in response to incoming nucleocapsids supports this
hypothesis.
The standard model of RIG-I activation implies that ligand
binding induces a conformational change followed by oligomer-
ization (Kowalinski et al., 2011; Saito et al., 2007; Takahasi et al.,
2008). Interestingly, oligomerization seems not to be a strict
consequence of the conformational switch. While infection with
the negative-stranded 50ppp-RNA viruses VSV, LACV, and
RVFV triggers both the conformational switch and the oligomer-
ization, infection with the positive-strand 50capped RNA virus
SFV triggers only the conformational switch. It is known that
innate immune recognition of SFV occurs mainly through
MDA5 with a modest contribution from RIG-I (Schulz et al.,
2010). VSV, LACV, and RVFV are mainly recognized by RIG-I
(Habjan et al., 2008a; Kato et al., 2006; Verbruggen et al.,
2011). Thus, a weak RIG-I trigger like SFV may only cause the
conformational switch, whereas stronger RIG-I triggers continue
to the subsequent oligomerization.
We have introduced Drosophila cells as a tool to establish that
RIG-I activation occurs independent of mammalian cofactors. In
mammalian cells, RIG-I is fine-tuned by inhibitors and cofactors.
The Drosophila cells, which can coexpress up to 12 different re-
combinant proteins (Yang and Reth, 2012), hold promise as342 Cell Host & Microbe 13, 336–346, March 13, 2013 ª2013 Elseviea system to reconstitute the RIG-I signaling complex for studying
the details of its regulation.
The classical studies on PRRs and PAMPs involved the usage
of purified RNA ligands. However, as we and others (Baum and
Garcı´a-Sastre, 2011; Kato et al., 2011) have pointed out, viral
RNAs in their physiological context are complexed with host
cell or viral proteins. Recent reports on the PRRs PKR and
TLR3 provide increasing evidence that protein-bound RNA
ligands are comparable or even more powerful PRR ligands
than naked RNAs (Dauber et al., 2009; Lai et al., 2011). It would
be interesting to test other PRRs for activation by physiological
nucleic acid-protein complexes.
In summary, our results indicate that RIG-I, the major intracel-
lular PRR for viral pathogens, is capable of recognizing the
50ppp-dsRNA of viral nucleocapsids. This enables a cytoplasmic
response to incoming negative-strand RNA viruses at the earliest
possible time point of infection.
EXPERIMENTAL PROCEDURES
Cells, Viruses, Plasmids, and Reagents
A549, 293T, and MEFs deficient in RIG-I, MDA5 (Kato et al., 2006), or MAVS
(Seth et al., 2005) were cultivated in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal calf serum (FCS) at 37C and 5%
CO2. D.Mel-2 cells (GIBCO) were cultivated in Spodopan (Pan Biotech)
at 28C with no additional CO2. VSV, SFV, FLUAVDNS1 (Garcı´a-Sastre
et al., 1998), RVFVDNSs::GFP (Habjan et al., 2008b; Kuri et al., 2010),r Inc.
Figure 7. Superresolution Immunofluorescence Microscopy of RIG-
I/LACV Nucleocapsid Complexes
CHX-treated A549 cells were infected with LACVdelNSs and analyzed 5 hr
later by GSD double immunofluorescence using antisera against LACV N
(green channel) or RIG-I (red channel). Four example areas with nucleocapsids
are shown. Scale bar represents 200 nm. See also Figure S6.
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(Blakqori et al., 2007) were propagated on Vero cells. Plasmids pI.18_RVFV_N,
pI.18_RVFV_L, pI.18_RVFV_M, and pHH21_RVFV_vMGFP were described
previously (Habjan et al., 2008b, 2009a). Plasmid pRmHA3-RIG-I was con-
structed by cloning a PCR-generated RIG-I complementary DNA (cDNA) frag-
ment into pRmHA3 (Bunch et al., 1988) using engineered 50 KpnI and 30 SalI
restriction sites. Primer sequences are available upon request. CHX, NH4Cl,
CuSO4, BRQ, and MA were from Sigma. PYF (NSC-143095) and CPEC
(NSC-375575) were kindly obtained from the Drug Synthesis and Chemistry
Branch of the National Cancer Institute.
Production of VLPs
RVFV VLPs were generated as described previously (Habjan et al., 2009a).
Briefly, subconfluent monolayers of 293T cells in 90 mm dishes were
transfected with 3 mg each of pI.18_RVFV_N, pI.18_RVFV_L, pI.18_RVFV_M,
and pHH21_RVFV_vMGFP (tc-VLPs), or pI.18_RVFV_N and pI.18_RVFV_M
only (ghost VLPs) usingNanofectin (PAALaboratories). At 5hr posttransfection,
medium was changed and 48 hr later supernatants collected and clarified
fromcell debris by centrifugation (6,0003g, 10min at 4C). VLPswere concen-
trated with Amicon Ultra-15 (Millipore) Ultracel-100 kDa filter devices.
Infection of Cells
Cells grown to 90% confluency were inoculated for 1 hr with viruses or
VLPs dissolved in 200 ml OptiMEM (Invitrogen; for mammalian cells) or Spodo-
pan (for insect cells) at a multiplicity of infection (moi) of 5. FLUAVDNS1 was
washed off with PBS, whereas for all other infections the inoculumwas directly
replaced with DMEM 5% FCS (mammalian cells) or Spodopan (insect cells). If
required, cells were pretreated with inhibitors dissolved in complete medium
for 1 hr (CHX, NH4Cl) or 24 hr (BRQ, MA, PYF, CPEC). The inhibitors were
also added to the virus inoculum and the incubation medium.
Real-Time RT-PCR
Cellular RNA was isolated with the NucleoSpin RNA II kit (Macherey-Nagel).
A total of 600 ng was used for cDNA synthesis and PCR employing theCell HoQuantiTect SYBR Green RT-PCR Kit (QIAGEN) and a LightCycler II (Roche).
mRNAs of human and murine IFN-b and ISG56 were detected with specific
QuantiTect primers (see Supplemental Information) and normalized against
g-actin (human cells) or GAPDH (murine cells) using the ddCT method (Livak
and Schmittgen, 2001). Upregulation of inducible genes is depicted in relation
to nonstimulated, noninfected (mock) cells.
siRNA Knockdown
Knockdown of gene expression was achieved by 2-fold reverse transfection of
siRNAs. siRNAs (25 nM each; see Supplemental Information) were diluted in
100 ml DMEM, mixed with 3 ml HiPerFect (QIAGEN), incubated for 10 min at
room temperature, and dropped onto a 12-well plate. Then, 1.5 3 105 cells
in DMEM 10% FCS were seeded on top. After 48 hr at 37C, cells were
harvested, counted, and 1.5 3 105 cells were again reverse transfected as
described.
Activation State of RIG-I
To assay the conformation of RIG-I, cells were lysed in PBS/0.5% Triton X-100
and incubated on ice for 10 min. Then, samples were sonified in a Branson
3200 Ultrasonic cleaner at 4C for 10 min and centrifuged at 4C for 10 min
at 10,000 3 g. An aliquot of 25 mg of total protein in 10 ml PBS was digested
for 25 min with 0.2 mg/ml L-1-tosylamido-2-phenylethyl chloromethyl ketone-
treated trypsin (Sigma-Aldrich) at 37C. Reaction was stopped by adding 53
sample buffer (250 mM Tris-HCl [pH 6.8], 10% SDS, 50% glycerol, 25%
b- mercaptoethanol [b-ME], 0.5% bromphenol blue) and heating at 95C for
5 min. Samples were subjected to 12% SDS-PAGE and western blot analysis
using mouse monoclonal anti-RIG-I antibody (ALME-1; Enzo Life Sciences) at
1:1,000. Staining of the blot with 0.1% Ponceau S in 5% acetic acid served as
a loading control.
To investigate the oligomerization of RIG-I, 50 mg of sonified cell lysate in
native loading buffer (50 mM Tris-HCl [pH 6.8], 10% glycerol, 0.1% bromphe-
nol blue) was loaded onto a nondenaturing 8% polyacrylamide gel. Proteins
were separated by electrophoresis with 50 mM Tris-NaOH (pH 9.0), 384 mM
glycin as anode buffer and 50 mM Tris (pH 8.3), 384 mM glycin, 1% sodium
deoxycholate as cathode buffer. Western blot analysis was performed as out-
lined above.
Immunofluorescence Assays
Cells were grown on coverslips to 30%–50% confluency, infected, and incu-
bated for the indicated time. Cells were fixed with 3% paraformaldehyde, per-
meabilized with 0.5% Triton X-100 in PBS, and washed three times with PBS.
Primary antibodies were diluted in PBS/1% FCS. Primary antibodies were
either rabbit polyclonal anti-LACV N (1:1,000) (Blakqori et al., 2007) or rabbit
polyclonal anti-RVFV N (1:1,000) (Lorenzo et al., 2008) combined with mouse
polyclonal anti-human RIG-I (1:200) (Baum et al., 2010). After 1 hr incubation at
room temperature, coverslips were washed three times in PBS then treated
with goat anti-rabbit Cy2 and goat anti-mouse Cy3 at a dilution of 1:200. After
washing three times in PBS, coverslips were mounted with Fluorsave solution
(Calbiochem) and examined using a Leica SP5 confocal microscope.
For the superresolution microscopy, a Leica SRGSDmicroscope was used.
Samples were prepared as described for confocal microscopy except that
goat anti-rabbit Alexa Fluor 488 (LACV N) and goat anti-mouse Alexa Fluor
647 (RIG-I) were employed as secondary antibody antibodies. Samples
were embedded in freshly prepared 100 mM b-mercaptoethylamine in PBS
(pH 7.4) directly before imaging.
Coimmunoprecipitation Assays
Cells grown in two T175 flasks were scraped off in 10 ml PBS, centrifuged at
low speed, and the pellets lysed in 1,050 ml RIPA buffer (prepared with
DEPC-treated H2O) containing protease inhibitors, incubated on ice for
30 min and centrifuged at 4C for 10 min at 10,000 3 g. Supernatants were
transferred to fresh tubes and 10% kept as input control. The remaining
90% of the lysates were subjected to immunoprecipitation (IP) using Dyna-
beads (Invitrogen). In parallel, 1.5 mg beads per IP were coupled with the
appropriate antibodies using the Dynabeads antibody coupling kit (Invitrogen).
For the anti-p21 and anti-RIG-I IPs, beads were coupled with rabbit polyclonal
anti-mouse antibody (DAKO); for the anti-LACV N IP, beads were coupled
with rabbit polyclonal anti-LACV N (each at a 1:200 dilution per IP); and forst & Microbe 13, 336–346, March 13, 2013 ª2013 Elsevier Inc. 343
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(Habjan et al., 2009b) for 20 hr at 37C. After antibody coupling, beads were
washed two times with RIPA buffer, and the anti-mouse antibody beads
were further incubated with mouse monoclonal anti-p21 (Santa Cruz Biotech-
nology) or mousemonoclonal anti-RIG-I antibody ALME-1 at a 1:200 dilution in
RIPA buffer for 2 hr at 4C. The beads were then incubated with the lysates for
2 hr at 4C and the immunoprecipitates washed three times with RIPA buffer
and then eluted with sample buffer (50 mM Tris-HCl [pH 6.8], 2% SDS, 10%
glycerol, 5% b-ME, 0.1% bromphenol blue) for 5 min at 95C. Eluates were
analyzed by western blotting using rabbit polyclonal anti-LACV N or anti-
RVFV N antisera (1:1,000), mouse monoclonal anti-RIG-I antibody ALME-1
(1:1,000), or mouse monoclonal anti-p21 (1:500). Protein A horseradish perox-
idase conjugate (Millipore; 1:10,000) was used for detection.
ADP-Aluminum Fluoride Trapping
ADP,AlF3 trapping was performed essentially as described elsewhere
(Chaney et al., 2001). Briefly, 50 mg cell protein was prepared in STA buffer
(25 mM Tris-acetate [pH 8.0], 8 mM Mg-acetate, 10 mM KCl, 3.5% w/v PEG
6000, 1 mM DTT) with 0.2 mM ADP and 10 mM NaF and incubated at 37C
for 5 min. After addition of 0.4 mM AlCl3, the reactions were incubated for
further 10 min and then supplemented with native loading buffer (50 mM
Tris-HCl [pH 6.8], 10% glycerol, 0.1% bromophenol blue). Native gel electro-
phoresis and western blot analysis were performed as described above.
Expression of RIG-I in Drosophila Cells
D.Mel-2 cells (13 107) resuspended in 10 ml Spodopan were transfected with
16 mg pRmHa3-RIG-I plasmid mixed with 48 ml Cellfectin (Invitrogen) and
incubated at 28C in T75 flasks. RIG-I expression was induced 48 hr later
with 1 mM CuSO4, and 24 hr later cells were scraped off in 10 ml PBS. Cells
were pelleted by 5 min centrifugation at 100 3 g and resuspended in 800 ml
RIPA buffer (for IPs) or in 150 ml 0.5% Triton X-100 in PBS (for RIG-I assays).
The suspensions were incubated for 10 min at 4C and centrifuged at
10,000 3 g, and the supernatants were kept at 4C.
Dialysis and ATP Supplementation of Cell Lysates
Visking dialysis tubing 27/32 with a diameter of 21 mm (Serva Electrophoresis)
was used to deplete cell lysates from low-molecular-weight compounds. The
membrane tubes were activated by submerging in H2O and boiling for 1 min in
the microwave oven, followed by a transfer into H2O at room temperature. For
cell lysates, 100 ml was dialyzed at 4C against PBS in 1 ml Eppendorf tubes
covered with the dialysis membrane. For nucleocapsids, 10 ml was dialyzed
using 200 ml PCR tubes. The buffer was exchanged after 1 hr, 12 hr, and
then again 1 hr later. To test the contribution of ATP, lysates or nucleocapsids
were first mixed and then incubated with or without 1 mM ATP for 1 hr at 37C.
The RIG-I conformational switch assay was performed as indicated above.
Purification of Viral Nucleocapsids
BHK cells seeded in ten T175 flasks were infected with virus at an moi of 0.01.
Cell supernatants were harvested at 3 days later and virions purified by centri-
fugation through a 30% glycerol cushion at 25,000 rpm for 1.5 hr at 4C in
a SW-32 rotor. Pellets were resuspended in hypotonic lysis buffer (10 mM
Tris/HCl [pH 7.8], 150 mM NaCl, 1 mM EDTA, 1% NP40) in the presence of
complete protease inhibitors (Roche). Nucleocapsids were purified in a CsCl
gradient as described elsewhere (Mavrakis et al., 2002), with minor modifica-
tions. Briefly, the cleared lysate was loaded on top of a continuous 20%–40%
CsCl gradient in 20 mM Tris/HCl (pH 7.9), 200 mM NaCl, centrifuged at
52,000 rpm for 2 hr at 12C in a SW60 rotor, and the recovered fraction pelleted
at 45,000 rpm for 1 hr at 4C in a TLA45 rotor. Nucleocapsids were resus-
pended in PBS and dialyzed against PBS to remove residual CsCl. Nucleo-
capsid-containing fractions were identified by SDS-PAGE with Coomassie
blue staining and western blot analysis.
Enzymatic Treatment of Lysates
Dialyzed lysates of RVFV-infected D.Mel-2 cells (50 mg protein in 10 ml) or
nucleocapsids were supplemented with 1 mM ATP and incubated either
with 5 mg RNase A, 1 U RNase III, or 2 U shrimp alkaline phosphatase (SAP)
for 1 hr at 37C. Samples were then mixed 1:1 with dialyzed lysates from
RIG-I-expressing D.Mel-2 cells (50 mg protein in 10 ml) and incubated for 1 hr344 Cell Host & Microbe 13, 336–346, March 13, 2013 ª2013 Elsevieat 37C. The RIG-I conformation assay was performed with half of the sample,
whereas the other half was kept as input control.
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